JHMM 📈 John Hancock Multifactor - Overview
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US47804J2069 • Mid-Cap Blend
JHMM: Mid-cap, Stocks, US, Equities
The John Hancock Multifactor Mid Cap ETF, listed on the NYSE ARCA under the ticker JHMM, is designed to track a specific index that focuses on mid-cap companies in the U.S. market. This index is constructed to include a subset of securities from the broader U.S. Universe, specifically targeting companies with market capitalizations that fall between the 200th and 951st largest U.S. companies at the time of reconstitution. By doing so, the fund aims to provide investors with exposure to a segment of the market that may offer a balance between growth potential and stability. The fund's investment strategy involves allocating at least 80% of its net assets, plus any borrowings for investment purposes, into the securities that make up its underlying index.
As an exchange-traded fund (ETF), JHMM offers investors the benefits of diversification and flexibility, allowing them to gain exposure to a broad range of mid-cap companies through a single investment vehicle. The fund's category is classified as Mid-Cap Blend, indicating that it seeks to balance value and growth characteristics within its portfolio. With its domicile in the United States and an ISIN of US47804J2069, the John Hancock Multifactor Mid Cap ETF is designed for investors looking to tap into the U.S. mid-cap market. For more information, investors can visit the company's website at http://jhinvestments.com, which provides detailed insights into the fund's strategy, performance, and other relevant information.
By investing in the John Hancock Multifactor Mid Cap ETF, investors can potentially benefit from the fund's multifactor approach, which aims to identify and capitalize on various drivers of return across different market conditions. This approach can help in mitigating risks and enhancing returns over the long term. Furthermore, as an ETF, JHMM offers the advantage of transparency, with its holdings and performance data readily available to investors. This transparency, combined with the fund's focus on mid-cap companies, makes it an attractive option for those seeking to diversify their portfolios and tap into the growth potential of the U.S. mid-cap market.
Additional Sources for JHMM ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
JHMM ETF Overview
Market Cap in USD | 4,027m |
Category | Mid-Cap Blend |
TER | 0.42% |
IPO / Inception | 2015-09-28 |
JHMM ETF Ratings
Growth 5y | 63.2% |
Fundamental | - |
Dividend | 49.0% |
Rel. Strength Industry | -18.6 |
Analysts | - |
Fair Price Momentum | 61.33 USD |
Fair Price DCF | - |
JHMM Dividends
Dividend Yield 12m | 0.98% |
Yield on Cost 5y | 1.60% |
Annual Growth 5y | 5.26% |
Payout Consistency | 95.9% |
JHMM Growth Ratios
Growth Correlation 3m | -1.2% |
Growth Correlation 12m | 89% |
Growth Correlation 5y | 71.9% |
CAGR 5y | 10.34% |
CAGR/Mean DD 5y | 1.28 |
Sharpe Ratio 12m | 1.13 |
Alpha | -6.46 |
Beta | 1.10 |
Volatility | 16.34% |
Current Volume | 157k |
Average Volume 20d | 220.3k |
As of January 18, 2025, the stock is trading at USD 62.16 with a total of 157,025 shares traded.
Over the past week, the price has changed by +4.58%, over one month by +0.82%, over three months by +2.05% and over the past year by +22.91%.
Yes. Based on ValueRay Analyses, John Hancock Multifactor (NYSE ARCA:JHMM) is currently (January 2025) a good stock to buy. It has a ValueRay Growth Rating of 63.24 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of JHMM as of January 2025 is 61.33. This means that JHMM is currently overvalued and has a potential downside of -1.34%.
John Hancock Multifactor has no consensus analysts rating.
According to ValueRays Forecast Model, JHMM John Hancock Multifactor will be worth about 68.4 in January 2026. The stock is currently trading at 62.16. This means that the stock has a potential upside of +10.07%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 68.4 | 10.1% |